News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioProcessors’ SimCell (Tm) Platform Demonstrates Potential To Increase Amgen’s (AMGN) Cell Culture Experiment Capacity


10/19/2005 5:09:32 PM

An announcement at Biochemical XIV Show disclosed the completion of an important phase of a long-term joint project with Amgen (NASDAQ:AMGN) aimed at evaluating BioProcessors’ SimCell (Tm) MicroBioreactor technology. This technology has the potential to increase Amgen’s mammalian cell culture process development capacity.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES